These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27497816)

  • 1. Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer.
    Kheshtchin N; Arab S; Ajami M; Mirzaei R; Ashourpour M; Mousavi N; Khosravianfar N; Jadidi-Niaragh F; Namdar A; Noorbakhsh F; Hadjati J
    Cancer Immunol Immunother; 2016 Oct; 65(10):1159-67. PubMed ID: 27497816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer.
    Schwartz DL; Bankson JA; Lemos R; Lai SY; Thittai AK; He Y; Hostetter G; Demeure MJ; Von Hoff DD; Powis G
    Mol Cancer Ther; 2010 Jul; 9(7):2057-67. PubMed ID: 20587661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24
    Minami T; Matsumura N; Sugimoto K; Shimizu N; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    Int Immunopharmacol; 2017 Mar; 44():197-202. PubMed ID: 28110220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.
    Welsh S; Williams R; Kirkpatrick L; Paine-Murrieta G; Powis G
    Mol Cancer Ther; 2004 Mar; 3(3):233-44. PubMed ID: 15026543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
    Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells
    Cecil DL; Slota M; O'Meara MM; Curtis BC; Gad E; Dang Y; Herendeen D; Rastetter L; Disis ML
    Clin Cancer Res; 2017 Jul; 23(13):3396-3404. PubMed ID: 28039264
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of miR-199a on rats with non-small cell lung cancer via regulating the HIF-1α/VEGF signaling pathway.
    Wang LM; Zhang LL; Wang LW; Zhu L; Ma XX
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10363-10369. PubMed ID: 31841190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
    Jacoby JJ; Erez B; Korshunova MV; Williams RR; Furutani K; Takahashi O; Kirkpatrick L; Lippman SM; Powis G; O'Reilly MS; Herbst RS
    J Thorac Oncol; 2010 Jul; 5(7):940-9. PubMed ID: 20512076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
    Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
    Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor.
    Lee K; Kim HM
    Arch Pharm Res; 2011 Oct; 34(10):1583-5. PubMed ID: 22076756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
    Yoon C; Chang KK; Lee JH; Tap WD; Hart CP; Simon MC; Yoon SS
    Oncotarget; 2016 Jul; 7(28):42844-42858. PubMed ID: 27374091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF-1α/GPER signaling mediates the expression of VEGF induced by hypoxia in breast cancer associated fibroblasts (CAFs).
    De Francesco EM; Lappano R; Santolla MF; Marsico S; Caruso A; Maggiolini M
    Breast Cancer Res; 2013; 15(4):R64. PubMed ID: 23947803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIF-1alpha and cancer therapy.
    Koh MY; Spivak-Kroizman TR; Powis G
    Recent Results Cancer Res; 2010; 180():15-34. PubMed ID: 20033376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimized Dose of Dendritic Cell-based Vaccination in Experimental Model of Tumor Using Artificial Neural Network.
    Mirsanei Z; Habibi S; Kheshtchin N; Mirzaei R; Arab S; Zand B; Jadidi-Niaragh F; Safvati A; Sharif-Paghaleh E; Arabameri A; Asemani D; Hajati J
    Iran J Allergy Asthma Immunol; 2020 Apr; 19(2):172-182. PubMed ID: 32372630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
    Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
    Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects and Mechanism of Action of PX-478 in Oxygen-Induced Retinopathy in Mice.
    Pan X; Lv Y
    Ophthalmic Res; 2020; 63(2):182-193. PubMed ID: 31955159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer.
    Luker AJ; Graham LJ; Smith TM; Camarena C; Zellner MP; Gilmer JS; Damle SR; Conrad DH; Bear HD; Martin RK
    BMC Immunol; 2020 Feb; 21(1):8. PubMed ID: 32106810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia-inducible factor 1 alpha limits dendritic cell stimulation of CD8 T cell immunity.
    Tran CW; Gold MJ; Garcia-Batres C; Tai K; Elford AR; Himmel ME; Elia AJ; Ohashi PS
    PLoS One; 2020; 15(12):e0244366. PubMed ID: 33382742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.